GENENTECH, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1976-01-01
- Employees
- 11.1K
- Market Cap
- -
- Website
- http://www.gene.com
A Study of Bevacizumab in Previously Untreated Extensive-Stage Small Cell Lung Cancer (SALUTE)
Phase 2
Completed
- Conditions
- Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2006-11-23
- Last Posted Date
- 2011-04-29
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 102
- Registration Number
- NCT00403403
A Study to Evaluate the Safety of Xolair in Moderate to Severe Persistent Asthma Patients (ALTO)
Phase 3
Completed
- Conditions
- Asthma
- First Posted Date
- 2006-11-20
- Last Posted Date
- 2014-03-19
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 1899
- Registration Number
- NCT00401596
A Study of Dulanermin in Combination With Rituximab in Subjects With Follicular and Other Low Grade, CD20+, Non-Hodgkin's Lymphomas
- First Posted Date
- 2006-11-17
- Last Posted Date
- 2011-11-23
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 72
- Registration Number
- NCT00400764
A Study of Tenecteplase for Restoration of Function in Dysfunctional Central Venous Catheters
Phase 3
Completed
- Conditions
- Dysfunctional Central Venous Access Catheters
- Interventions
- First Posted Date
- 2006-11-06
- Last Posted Date
- 2011-04-27
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 251
- Registration Number
- NCT00396318
A Study of Tenecteplase for Restoration of Function in Dysfunctional Hemodialysis Catheters
Phase 3
Completed
- Conditions
- Dysfunctional Hemodialysis Catheters
- Interventions
- Drug: placebo
- First Posted Date
- 2006-11-06
- Last Posted Date
- 2010-06-03
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 150
- Registration Number
- NCT00396032
A Study of Tenecteplase for Restoration of Function in Dysfunctional Central Venous Catheters
Phase 3
Completed
- Conditions
- Dysfunctional Central Venous Access Catheters
- Interventions
- Drug: placebo
- First Posted Date
- 2006-11-06
- Last Posted Date
- 2010-08-10
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT00395876
A Study of Tenecteplase for Restoration of Function in Dysfunctional Hemodialysis (HD) Catheters
- First Posted Date
- 2006-11-06
- Last Posted Date
- 2017-01-12
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 223
- Registration Number
- NCT00396253
A Study of Avastin in Combination With Chemotherapy for Treatment of Colorectal Cancer and Non-Small Cell Lung Cancer (ARIES)
Completed
- Conditions
- Colorectal CancerNon-Small Cell Lung Cancer
- First Posted Date
- 2006-10-16
- Last Posted Date
- 2022-12-12
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 3998
- Registration Number
- NCT00388206
A Study to Evaluate the Effects of Efalizumab on Immune Responses in Subjects With Moderate Plaque Psoriasis
Phase 1
Completed
- Conditions
- Plaque Psoriasis
- First Posted Date
- 2006-09-29
- Last Posted Date
- 2006-09-29
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT00382512
A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus Erythematosus
Phase 3
Terminated
- Conditions
- Lupus Erythematosus, Systemic
- Interventions
- First Posted Date
- 2006-09-28
- Last Posted Date
- 2017-08-01
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 31
- Registration Number
- NCT00381810
- Locations
- 🇺🇸
Arizona Arthritis & Rheumatology Research, Pllc, Paradise Valley, Arizona, United States
🇺🇸Eden Medical Center San Leandro Hospital, San Leandro, California, United States
🇺🇸Intermountain Research Center, Boise, Idaho, United States
© Copyright 2025. All Rights Reserved by MedPath